On Thursday, H.C. Wainwright maintained a positive outlook on shares of Tenaya Therapeutics Inc (NASDAQ:TNYA), reiterating a Buy rating and a price target of $18.00. The endorsement follows the announcement that the Independent Data Safety and Monitoring Board (DSMB) has given the green light for Tenaya's TN-201 Phase 1b/2 MyPEAK-1 study to advance to Cohort 2.
This next phase involves a higher dose of the gene therapy being tested for MYBPC3-associated Hypertrophic Cardiomyopathy (HCM).
The MyPEAK-1 study is focused on establishing the safety profile of TN-201, Tenaya's gene therapy candidate. The progression to Cohort 2, which will test a 6e13 vg/kg dose, comes after a successful assessment of the therapy's tolerability at a 3e13 vg/kg dose in Cohort 1. This initial cohort included three patients who did not experience unexpected adverse reactions or drug-related toxicities.
To better support the future development of TN-201, Tenaya has made several protocol adjustments. These include the addition of a baseline biopsy, bringing the total number of biopsies to three, the inclusion of patients with either non-obstructive or obstructive forms of HCM, and the expansion of the potential number of patients in the dose-expansion phase of the trial from nine to 24 adults.
The company anticipates initial results from Cohort 1 by the end of 2024. These results are expected to encompass safety data, analyses from cardiac biopsies, and changes in cardiac biomarkers. According to H.C. Wainwright, these forthcoming results represent a significant driver for the gene therapy program, reinforcing the firm's confidence in Tenaya and its $18 price target.
In other recent news, the company has also announced several modifications to the trial protocol, including the addition of a baseline biopsy and an increase in the potential number of participants from nine to 24 adults. Tenaya expects to release initial results from the first cohort by the end of 2024, providing crucial safety data and insights from cardiac biopsies.
Canaccord Genuity, and Leerink Partners have maintained positive outlooks on Tenaya, with price targets of $16, and $8, respectively.
In a parallel move, Tenaya has introduced a new 2024 Inducement Equity Incentive Plan, allowing for the issuance of 1,200,000 shares of common stock. The company also announced the upcoming departure of Leone Patterson, its Chief Financial and Business Officer, initiating a search for a new CFO. These recent developments highlight Tenaya's ongoing efforts in advancing its gene therapy program.
InvestingPro Insights
Recent InvestingPro data provides additional context to Tenaya Therapeutics' (NASDAQ:TNYA) financial position as it advances its gene therapy program. The company's market capitalization stands at $169.61 million, reflecting investor sentiment towards its potential in the biotechnology sector.
InvestingPro Tips highlight that Tenaya holds more cash than debt on its balance sheet, which is crucial for a biotech company in the developmental stage. This financial cushion may provide the necessary runway for the company to continue its clinical trials and research activities. Additionally, three analysts have revised their earnings upwards for the upcoming period, suggesting growing optimism about Tenaya's prospects.
However, it is important to note that Tenaya is currently not profitable, with a negative P/E ratio of -1.4 over the last twelve months as of Q2 2024. This is not uncommon for biotech companies in the research and development phase, but it underscores the importance of successful clinical outcomes for the company's future.
The stock has shown significant volatility, with a 21.47% return over the last week but a -49.88% return over the past six months. This volatility aligns with the nature of biotech stocks, which can experience sharp movements based on clinical trial results and regulatory decisions.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Tenaya Therapeutics, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.